Pipeline

Cipher is continually seeking to acquire and develop promising product candidates with the potential to transform the standard of care in dermatology. Our growing pipeline includes both late-stage products and earlier-stage assets that address unmet medical needs.

United States
Canada
Europe
Candidate | indication
Pre-Clinical
Phase I
Phase II
Phase II/III
Phase III
Regulatory Review
Approval
Market

Cipher has also acquired six pre-clinical compounds for the treatment of melanoma and other cancers. The clinical plan for these compounds has not yet been established.

a) Cipher has worldwide rights.
b) Pruridexin is under review by European Medicines Agency.
c) Dermadexin has CE Mark in EU.
d) ASF-1096 was awarded orphan drug status in EU.
e) Dermadexin is under review by FDA as a 510-k.

Dermadexin™ | Seborrheic Dermatitis

Dermadexin™ is a patent-protected topical barrier-repair cream containing P3GCM. It received approval in the European Union (EU) in 2014 as a Class III medical device for the alleviation of symptoms of facial dermatitis such as redness, scaling and itching.

Sitavig™ | Cold Sores

Sitavig® is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.

Pruridexin™ | Chronic Pruritus

Pruridexin™ is a patent-protected topical cream being developed for the treatment of chronic pruritus (itching). It is currently under review by the European Medicines Agency as a Class III medical device.

Ozenoxacin | Impetigo

Ozenoxacin is a product candidate in Phase III that is being investigated as a topical cream for the treatment of acute dermatological infections. The bactericidal action of Ozenoxacin has demonstrated in vitro and in vivo antibacterial activity against a broad range of pathologically relevant bacteria, including methicillin-resistant Staphylococcus aureus strains and clinical isolates of organisms with emerging resistance to quinolones and other topical antibiotics.

CF101 | Plaque Psoriasis

CF101, an A3 adenosine receptor agonist, is a product candidate in Phase II/III that is being investigated as a treatment for plaque psoriasis. CF101 is a novel, first-in-class, small molecule, orally bioavailable drug.

CF101 | Rheumatoid Arthritis

CF101, an A3 adenosine receptor agonist, is a product candidate in Phase II/III that is being investigated as a treatment for rheumatoid arthritis. CF101 is a novel, first-in-class, small molecule, orally bioavailable drug.

ASF-1096 | Discoid Lupus Erythematosus

ASF-1096 is a product candidate in Phase II that is being investigated as a treatment for discoid lupus erythematosus, a severe, chronic, inflammatory and disfiguring skin disease that affects about 3 out of 10,000 in the general population. ASF-1096 has been awarded orphan drug status in the EU.

Nanolipolee-007 | Late Stage Melanoma

Nanolipolee-007 is a product candidate in pre-clinical development that is being investigated for the treatment of late-stage melanoma. Nanolipolee-007 is a first-in-class cholesterol-transport inhibitor that has demonstrated anti-proliferative activity against certain melanoma cell lines (including B-RAF resistant strains) in vitro as well as in early in vivo mouse studies.

Tattoo Removal Cream | Tattoo Removal

Tattoo Removal Cream is a topical product candidate in pre-clinical development for the removal or reduction of the appearance of tattoos.